Determinants of response to inhaled extrafine triple therapy in asthma : analyses of TRIMARAN and TRIGGER
BACKGROUND: A number of single-inhaler triple therapies are being developed for asthma, including the extrafine formulation of beclometasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium (G). Given asthma is a heterogenous disease, we investigated whether the clinical response to the addition of the long-acting muscarinic antagonist component within inhaled triple therapy was impacted by a range of clinical characteristics.
METHODS: These were pre-specified and post-hoc sub-group analyses of TRIMARAN and TRIGGER, which were double-blind, 52-week studies comparing medium-strength (100/6/10 µg; TRIMARAN) and high-strength (200/6/10 µg; TRIGGER) BDP/FF/G with the respective BDP/FF strengths in adults with uncontrolled asthma and a history of ≥ 1 exacerbation. Co-primary endpoints were pre-dose forced expiratory volume in 1 s (FEV1) at Week 26 and the rate of moderate-to-severe exacerbations over 52 weeks. Key secondary endpoints: peak FEV1 at Week 26 and average morning peak expiratory flow over the first 26 weeks in each study, and severe exacerbation rate over 52 weeks (pooled data).
RESULTS: Baseline clinical characteristics (pre-specified analyses) had no consistent effect on the lung function improvements with BDP/FF/G. For the exacerbation endpoints, sub-groups with higher reversibility gained greatest relative benefit from BDP/FF/G versus BDP/FF. In post-hoc analyses with patients sub-grouped by screening blood eosinophil values, in TRIMARAN the greatest relative effect of BDP/FF/G versus BDP/FF on the lung function endpoints was in the ≤ 300 cells/µL group; in TRIGGER, eosinophil levels did not markedly influence the relative efficacy of BDP/FF/G versus BDP/FF. Eosinophil levels did not influence relative efficacy on moderate-to-severe or severe exacerbations.
CONCLUSION: Overall, the relative efficacy of extrafine BDP/FF/G versus BDP/FF was not influenced by a range of clinical characteristics. However, some patient sub-groups gained additional benefit from BDP/FF/G for certain endpoints. In particular, for exacerbations the relative efficacy of BDP/FF/G was greater in more reversible patients. Trial registration ClinicalTrials.gov: TRIMARAN, NCT02676076 (registered February 8, 2016, https://clinicaltrials.gov/ct2/show/NCT02676076?term=NCT02676076&draw=2&rank=1 ,); TRIGGER, NCT02676089 (registered February 8, 2016, https://clinicaltrials.gov/ct2/show/NCT02676089?term=NCT02676089&draw=2&rank=1 ).
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
---|---|
Enthalten in: |
Respiratory research - 21(2020), 1 vom: 29. Okt., Seite 285 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Singh, Dave [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 20.08.2021 Date Revised 20.08.2021 published: Electronic ClinicalTrials.gov: NCT02676076, NCT02676089 Citation Status MEDLINE |
---|
doi: |
10.1186/s12931-020-01558-y |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM316900419 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM316900419 | ||
003 | DE-627 | ||
005 | 20231225162101.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s12931-020-01558-y |2 doi | |
028 | 5 | 2 | |a pubmed24n1056.xml |
035 | |a (DE-627)NLM316900419 | ||
035 | |a (NLM)33121501 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Singh, Dave |e verfasserin |4 aut | |
245 | 1 | 0 | |a Determinants of response to inhaled extrafine triple therapy in asthma |b analyses of TRIMARAN and TRIGGER |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 20.08.2021 | ||
500 | |a Date Revised 20.08.2021 | ||
500 | |a published: Electronic | ||
500 | |a ClinicalTrials.gov: NCT02676076, NCT02676089 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a BACKGROUND: A number of single-inhaler triple therapies are being developed for asthma, including the extrafine formulation of beclometasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium (G). Given asthma is a heterogenous disease, we investigated whether the clinical response to the addition of the long-acting muscarinic antagonist component within inhaled triple therapy was impacted by a range of clinical characteristics | ||
520 | |a METHODS: These were pre-specified and post-hoc sub-group analyses of TRIMARAN and TRIGGER, which were double-blind, 52-week studies comparing medium-strength (100/6/10 µg; TRIMARAN) and high-strength (200/6/10 µg; TRIGGER) BDP/FF/G with the respective BDP/FF strengths in adults with uncontrolled asthma and a history of ≥ 1 exacerbation. Co-primary endpoints were pre-dose forced expiratory volume in 1 s (FEV1) at Week 26 and the rate of moderate-to-severe exacerbations over 52 weeks. Key secondary endpoints: peak FEV1 at Week 26 and average morning peak expiratory flow over the first 26 weeks in each study, and severe exacerbation rate over 52 weeks (pooled data) | ||
520 | |a RESULTS: Baseline clinical characteristics (pre-specified analyses) had no consistent effect on the lung function improvements with BDP/FF/G. For the exacerbation endpoints, sub-groups with higher reversibility gained greatest relative benefit from BDP/FF/G versus BDP/FF. In post-hoc analyses with patients sub-grouped by screening blood eosinophil values, in TRIMARAN the greatest relative effect of BDP/FF/G versus BDP/FF on the lung function endpoints was in the ≤ 300 cells/µL group; in TRIGGER, eosinophil levels did not markedly influence the relative efficacy of BDP/FF/G versus BDP/FF. Eosinophil levels did not influence relative efficacy on moderate-to-severe or severe exacerbations | ||
520 | |a CONCLUSION: Overall, the relative efficacy of extrafine BDP/FF/G versus BDP/FF was not influenced by a range of clinical characteristics. However, some patient sub-groups gained additional benefit from BDP/FF/G for certain endpoints. In particular, for exacerbations the relative efficacy of BDP/FF/G was greater in more reversible patients. Trial registration ClinicalTrials.gov: TRIMARAN, NCT02676076 (registered February 8, 2016, https://clinicaltrials.gov/ct2/show/NCT02676076?term=NCT02676076&draw=2&rank=1 ,); TRIGGER, NCT02676089 (registered February 8, 2016, https://clinicaltrials.gov/ct2/show/NCT02676089?term=NCT02676089&draw=2&rank=1 ) | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Randomized Controlled Trial | |
650 | 4 | |a Asthma | |
650 | 4 | |a Eosinophils | |
650 | 4 | |a Inhaled corticosteroids | |
650 | 4 | |a Long-acting muscarinic antagonists | |
650 | 4 | |a Long-acting β2-agonists | |
650 | 4 | |a Pharmacotherapy | |
650 | 4 | |a Subgroup analyses | |
650 | 7 | |a Bronchodilator Agents |2 NLM | |
650 | 7 | |a Muscarinic Antagonists |2 NLM | |
650 | 7 | |a Beclomethasone |2 NLM | |
650 | 7 | |a KGZ1SLC28Z |2 NLM | |
650 | 7 | |a Glycopyrrolate |2 NLM | |
650 | 7 | |a V92SO9WP2I |2 NLM | |
650 | 7 | |a Formoterol Fumarate |2 NLM | |
650 | 7 | |a W34SHF8J2K |2 NLM | |
700 | 1 | |a Virchow, Johann Christian |e verfasserin |4 aut | |
700 | 1 | |a Canonica, Giorgio Walter |e verfasserin |4 aut | |
700 | 1 | |a Vele, Andrea |e verfasserin |4 aut | |
700 | 1 | |a Kots, Maxim |e verfasserin |4 aut | |
700 | 1 | |a Georges, George |e verfasserin |4 aut | |
700 | 1 | |a Papi, Alberto |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Respiratory research |d 2000 |g 21(2020), 1 vom: 29. Okt., Seite 285 |w (DE-627)NLM115627553 |x 1465-993X |7 nnns |
773 | 1 | 8 | |g volume:21 |g year:2020 |g number:1 |g day:29 |g month:10 |g pages:285 |
856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12931-020-01558-y |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 21 |j 2020 |e 1 |b 29 |c 10 |h 285 |